Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (28)
2024
-
Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials
Seminars in Arthritis and Rheumatism, Vol. 65
-
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Journal of Extracellular Vesicles, Vol. 13, Núm. 2
-
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments
Seminars in Arthritis and Rheumatism, Vol. 65
2021
-
Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach
Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
-
Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
Cancer Medicine, Vol. 10, Núm. 17, pp. 5748-5756
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment
Lung Cancer, Vol. 150, pp. 90-96
-
Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer
European Urology, Vol. 78, Núm. 5, pp. 652-656
-
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654
-
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422
2019
-
Association analyses identify 31 new risk loci for colorectal cancer susceptibility
Nature Communications, Vol. 10, Núm. 1
-
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion
European Journal of Cancer, Vol. 120, pp. 54-64
2018
-
Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy
Journal of Clinical Oncology, Vol. 36, Núm. 31, pp. 3134-3143
2016
-
Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial
Annals of Oncology, Vol. 27, pp. vi68
-
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356
Autophagy
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, Vol. 12, Núm. 1, pp. 1-222
2013
-
Spitzoid and non-spitzoid melanoma in children. A prognostic comparative study
Journal of the European Academy of Dermatology and Venereology, Vol. 27, Núm. 10, pp. 1214-1221